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Background: Human immunodeficiency virus type 1 (HIV-1) undergoes a protease-mediated maturation process
that is required for its infectivity. Little is known about how the physical properties of viral particles change during
maturation and how these changes affect the viral lifecycle. Using Atomic Force Microscopy (AFM), we previously
discovered that HIV undergoes a “stiffness switch”, a dramatic reduction in particle stiffness during maturation that
is mediated by the viral Envelope (Env) protein.
Results: In this study, we show that transmembrane-anchored Env cytoplasmic tail (CT) domain is sufficient to
regulate the particle stiffness of immature HIV-1. Using this construct expressed in trans with viral Env lacking the
CT domain, we show that increasing particle stiffness reduces viral entry activity in immature virions. A similar effect
was also observed for immature HIV-1 pseudovirions containing Env from vesicular stomatitis virus.
Conclusions: This linkage between particle stiffness and viral entry activity illustrates a novel level of regulation for
viral replication, providing the first evidence for a biological role of virion physical properties and suggesting a new
inhibitory strategy.
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The main structural component of an HIV-1 particle is
the viral Gag polyprotein, which polymerizes to form a
protein shell surrounded by a lipid membrane. Expres-
sion of Gag alone is necessary and sufficient for viral
particle assembly and budding [1]. The viral surface con-
tains the envelope protein (Env), which is synthesized as
a precursor (gp160) that is cleaved by a cellular protease
into receptor-binding (gp120) and transmembrane
(gp41) subunits. gp120 and gp41 form a noncovalent
complex that mediates viral entry [2,3]. The Env trans-
membrane subunit of HIV-1 and other lentiviruses has
an unusually long (~150 amino acids) cytoplasmic tail
(CT) domain compared to other retroviruses (~20-30
amino acids). Gag interacts with Env via CT, which aids
Env localization to viral budding sites and efficient in-
corporation into virions [4-6].* Correspondence: kay@biochem.utah.edu; roussoi@bgu.ac.il
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reproduction in any medium, provided the orDuring the viral lifecycle, a virion needs to meet sev-
eral distinct demands—efficient membrane fusion during
entry, particle disassembly to release genetic material,
assembly during budding, and stability in the extracellu-
lar environment before entry into the next cell. HIV-1
virions initially emerge from infected cells as immature
particles. These particles then undergo a maturation
process induced by HIV-1 protease cleavage of Gag into
several products including three structural proteins:
MA, CA and NC [7]. Electron Microscopy (EM) shows
that HIV-1 particles undergo a dramatic morphological
change from a roughly spherically symmetric immature
particle with a thick protein shell to a mature particle
with a prominent conical core (capsid) formed by CA
[8]. In mature virions, only MA remains associated with
the viral membrane, creating a thin protein shell. Because
of this striking morphological change and the requirement
to address diverse needs throughout their lifecycle, we
hypothesized that the physical properties of viral particles
would also change during maturation. Atomic force mi-
croscopy (AFM) has proven to be uniquely informative for
measuring the mechanical properties of viral particles
under native conditions. We and others have used AFM to
measure the physical properties of several viruses [9-12].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic of experimental strategy for separation of
Env entry and stiffness activites. A WT immature particle (top)
contains the full Env protein, including ectodomain and CT.
Immature virions bearing ΔCT Env (middle left) retain viral entry
activity, but lose particle stiffness, while immature particles bearing
GFP-TM1 (middle right) lack any entry activity due to their missing
Env ectodomain, but retain particle stiffness. Titration of GFP-TM1
into immature particles containing ΔCT Env (bottom) allows
measurement of how increasing particle stiffness affects entry
activity.
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particles are ~14-fold stiffer than mature ones, reflecting
a dramatic biophysical change during maturation that
we call the “stiffness switch” [13]. Further studies deter-
mined that Env CT is required for the stiffness switch, as
its deletion softens immature HIV-1 particles almost to the
mature level [13]. Immature HIV-1 virions are not infec-
tious due to both entry and post-entry (e.g., integration)
defects [14,15]. Deletion of CT restores the entry activity
of immature HIV-1 to the mature level [13-15]. These
results suggest a strong inverse correlation between viral
particle stiffness and entry activity. However, deletion of
CT has been reported to induce conformational changes
in gp120, which could affect viral entry activity [16]. There-
fore, a cause and effect relationship between particle stiff-
ness and viral entry has not yet been demonstrated, and
the link between virion physical properties and biological
function remains an open question.
In this study, we ask whether virion stiffness directly reg-
ulates its entry activity. To isolate the effect of particle stiff-
ness on viral entry, we designed constructs that separate
Env’s fusion and stiffness-mediating activities (Figure 1).
Using these constructs, we show that membrane-anchored
CT alone can stiffen immature HIV-1 particles in a
concentration-dependent manner. Increasing particle stiff-
ness inversely regulates viral entry mediated by either coex-
pressed HIV-1 ΔCT Env or an unrelated viral envelope
protein (VSVg). This study provides the first direct evi-
dence showing that particle stiffness regulates viral entry
activity, linking a virion’s physical and biological properties.
Our studies define a new regulatory level for viral replica-
tion and suggest a new strategy for the development of
novel HIV-1 inhibitors.
Results
In order to measure the effect of Env incorporation levels
on immature virion stiffness, we generated immature
HIV-1 with increasing amounts of WT Env by titrating
Env plasmid input during transfection. To produce im-
mature virions, we use a viral genome containing Gag
with mutated protease sites (immature genome), thus
preventing the proteolytic processing of full-length Gag
and viral maturation. WT Env was detected by anti-CT
antibody and Env incorporation levels were calculated as
a CT:Gag ratio. Mature particles are produced using a
WT genome that contains WT Gag, which is cleaved by
HIV protease during maturation. WT Env incorporation
in immature HIV-1 gradually increases viral particle stiff-
ness (Figure 2A).
CT alone is sufficient to regulate immature viral particle
stiffness
As we previously reported [13], HIV-1 Env, specifically the
CT domain, is necessary to produce stiff immatureparticles. To discern whether CT alone can stiffen viral
particles, we first deleted the Env ectodomain (all of gp120
and most of gp41), leaving the gp41 transmembrane (TM)
and CT domains. This construct was poorly incorporated
into virions, and introduction of a soluble trimeric coiled-
coil ectodomain (to mimic trimeric Env) did not improve
incorporation (data not shown). Next, we reasoned that
replacing gp120 with a soluble globular protein like GFP
might improve incorporation. Using GFP to replace the
ectodomain, but leaving TM and CT intact (GFP-TM1)
resulted in efficient incorporation (data not shown).
To investigate whether GFP-TM1 can stiffen viral parti-
cles similarly to WT Env, we generated immature particles
with escalating amounts of GFP-TM1. As with Env, GFP-
TM1 incorporation levels were calculated as a CT:Gag
ratio. Increasing GFP-TM1 incorporation also gradually
stiffens immature particles to beyond the WT immature
level (Figure 2B). These data show that CT alone is suffi-
cient to stiffen immature viral particles in a similar manner
to WT Env.
Figure 2 Env and GFP-TM1 incorporation levels correlate with immature particle stiffness. Different amounts of WT Env (A) or GFP-TM1 (B)
were incorporated into immature HIV-1, and the particle stiffness of these viruses was measured using AFM. At least 16 particles were measured
for each stiffness value, except the two highest GFP-TM1 points, which produced low particle yields (4 and 6 particles measured, respectively).
Viral particle stiffness is plotted against Env or GFP-TM1 incorporation levels normalized to virus with highest level of incorporation (open circles,
linear fit shown). The GFP-TM1 titration series was analyzed together with immature WT (filled circle). Error bars show SEM.
Figure 3 ΔCT coexpression slightly increases GFP-TM1
incorporation. GFP-TM1 was incorporated in immature HIV-1 with
or without ΔCT Env. 1X corresponds to 100% GFP-TM1 plasmid
input amount. For 0.5X or 1X GFP-TM1, ΔCT plasmid input was
replaced by the same amount of an inert bacterial vector (pCDF-BS)
to balance plasmid mass during transfection. Input amount of all
other plasmids (i.e., genome and GFP-TM1) remain the same with
the corresponding viruses bearing ΔCT. CT incorporation levels are
normalized to that of immature WT. Error bars indicate the SEM.
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Both viral stiffness and entry are controlled by Env. To
investigate whether particle stiffness directly regulates
viral entry, we separated Env’s stiffness-mediating and
entry-inducing domains. GFP-TM1 stiffens viral particles
without introducing entry activity (due to its missing
ectodomain). ΔCT Env efficiently mediates entry, but
contributes little to particle stiffness [13]. These con-
structs allow us to modulate virion stiffness as an inde-
pendent variable to determine its effect on viral entry
activity.
We produced immature virions with varying amounts
of GFP-TM1 (to modulate stiffness) and a fixed amount
of ΔCT Env (to provide entry activity). GFP-TM1 and
ΔCT Env incorporation levels were measured by WB as
CT:Gag and gp120:Gag ratios, respectively. The specific
entry activities of viruses with different GFP-TM1 in-
corporation levels were measured by a viral fusion
(BlaM) assay and normalized to corresponding ΔCT
viruses with no GFP-TM1.
Coexpression with ΔCT mildly increases GFP-TM1 in-
corporation relative to GFP-TM1 alone (Figure 3). As
with GFP-TM1 alone, GFP-TM1 incorporation in the
presence of ΔCT Env gradually increases immature par-
ticle stiffness (Figure 4A). As previously reported, Env
with intact CT has little effect on mature particle stiff-
ness [13]. Therefore, a GFP-TM1 titration series in ma-
ture virions serves as a control to isolate the effects of
GFP-TM1 incorporation on viral entry independent of
changing particle stiffness.
Figure 4 Particle stiffness regulates immature HIV-1 entry. Varying amounts of GFP-TM1 were incorporated into immature or mature HIV-1
bearing ΔCT Env (HXB2). The gp120 level represents all Env capable of mediating viral entry (ΔCT or WT Env). Error bars show SEM. Immature
(orange dash) viruses bearing different amounts of GFP-TM1 were generated and analyzed together with immature WT (blue diamond) or mature
WT (blue circle). (A) Virion stiffness (at least 19 particles were measured for each stiffness value) or (B) viral entry activity per Env normalized to
the corresponding mature or immature ΔCT viruses.
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ation greatly impairs viral entry activity in immature ΔCT
particles, while causing only modest reduction in the
corresponding mature particles. This result strongly sug-
gests that GFP-TM1 incorporation affects viral entryFigure 5 GFP-TM1 incorporation reduces viral yield and gp160 proce
levels of GFP-TM1 and ΔCT were generated together with WT virus. 1X sta
Viral yield (Gag per ml) is normalized to the yield of ΔCT virus. B). Ratio of
for ΔCT Env) is plotted.activity through changing particle stiffness. Besides viral
entry activity, we also observed that increasing GFP-TM1
incorporation reduces viral yield and gp160 processing
(cleavage to gp120 and gp41) (Figure 5). Since gp160 pro-
cessing is required for HIV-1 entry [7], this change couldssing. Immature (circles) and mature (squares) HIV-1 bearing different
nds for 100% GFP-TM1 plasmid input. Error bars indicate the SEM. A).
processed Env (gp120) to unprocessed Env (gp160 for WT Env; gp140
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entry. However, gp160 processing declines similarly in both
the immature and mature states, suggesting that the
immature-specific changes in entry activity are not due to
changes in gp160 processing (Figure 5). Nevertheless, poor
gp160 processing reduces gp120 incorporation, in some
cases to a level below the detection limit. As a result, the
entry activity for virus with 200% GFP-TM1 plasmid input
could not be accurately quantified.
In all of the above studies, we used HXB2, a commonly
studied CXCR4-tropic laboratory HIV-1 strain [9,13]. We
investigated whether the entry-suppressing effect of GFP-
TM1 is general for HIV by studying JRFL, a primary
CCR5-tropic strain, by coexpressing GFP-TM1 with JRFL
ΔCT Env on mature or immature virions. An immature-
specific loss of viral entry activity was observed with
increasing GFP-TM1 incorporation, as seen with HXB2
ΔCT Env (Figure 6). In contrast to HXB2 ΔCT, increasing
GFP-TM1 incorporation reduces JRFL ΔCT Env incorpor-
ation but not gp160 processing (data not shown). This ob-
servation further suggests that neither incorporation nor
processing of Env contributes significantly to the
immature-specific effect on viral entry induced by GFP-
TM1 incorporation.Figure 6 GFP-TM1 incorporation reduces viral entry mediated
by JRFL ΔCT Env. Titrating amounts of GFP-TM1 were incorporated
in immature (hollow diamond) or mature (hollow circle) HIV-1
bearing JRFL ΔCT Env. Immature (solid diamond) or mature (solid
circle) JRFL WT viruses were also generated within the same batch
as controls. CT incorporation levels (representing GFP-TM1 or WT
Env) are normalized to those of the corresponding immature or
mature viruses with 100% GFP-TM1 plasmid input. Specific viral entry
activity is normalized to those of the corresponding immature or
mature ΔCT viruses with no GFP-TM1. Error bars indicate the SEM.Particle stiffness regulates viral entry of immature
pseudovirions coated with VSVg
HIV-1 is generally thought to enter target cells at the
plasma membrane, though a recent report suggests endo-
cytosis as the primary entry route [17]. VSV, as a member
of the Rhabdoviridae family, is unrelated to HIV-1 and
enters target cells via endocytosis. VSV entry is mediated
by its Env, VSVg [17-19]. Compared to HIV-1 Env, VSVg
incorporates at much higher levels, requires no protease
cleavage to mediate entry, and is unlikely to interact with
GFP-TM1. Investigating the effect of GFP-TM1 incorpor-
ation on entry activity of HIV-1 pseudovirions coated with
VSVg therefore provides an independent test of the rela-
tionship between particle stiffness and viral entry.
As with HIV-1 ΔCT Env, GFP-TM1 and VSVg were
coexpressed and incorporated into mature or immature
HIV-1 virions. WB was used to quantify GFP-TM1 and
VSVg incorporation level as CT:Gag and VSVg:Gag ratio,
respectively. Increasing GFP-TM1 incorporation increases
particle stiffness in immature virions (Figure 7A). Similar
to the effect on HIV-1 entry, increasing GFP-TM1 incorp-
oration greatly reduces VSVg-mediated entry in immature
virions with much less effect on mature virions
(Figure 7B). VSVg incorporation level changes little with
increasing GFP-TM1 incorporation (data not shown).
These results further suggest that particle stiffness directly
regulates viral entry.
GFP-TM1 does not interact with viral Env
An important assumption of our study is that GFP-TM1
incorporation does not affect viral entry mediated by ΔCT
Env or VSVg except by changing particle stiffness. As dis-
cussed earlier, GFP-TM1 cannot mediate viral entry itself,
and GFP-TM1 is missing the critical self-associating resi-
dues of the gp41 ectodomain required for Env trimeriza-
tion [20,21]. Nevertheless, there is still the possibility that
GFP-TM1 interacts with ΔCT Env or VSVg.
To rule out this possibility, we used a non-ionic deter-
gent, Triton X-100 (TX100), which does not dissociate
WT Env from the immature Gag shell due to the noncova-
lent CT-Gag interaction, but removes Env with truncated
CT [5,6]. Treating immature virions bearing both GFP-
TM1 and JRFL ΔCT Env with TX100, GFP-TM1 remains
associated with the Gag shell while almost all JRFL ΔCT
Env dissociates (Figure 8). This result suggests that there is
no specific interaction between GFP-TM1 and ΔCT Env.
A similar result was observed for VSVg pseudovirions
expressing GFP-TM1 (data not shown).
Modest reduction of mature viral entry is likely due to
over expression of exogenous protein on the viral
membrane
Although relatively immature-specific, GFP-TM1 does
cause modest loss of viral entry activity in the mature
Figure 7 Particle stiffness regulates immature entry mediated by VSVg. Varying amounts of GFP-TM1 were incorporated into immature or
mature HIV-1 bearing VSVg. Anti-VSVg antibody was used to quantify VSVg levels by WB. Viral entry activity was normalized by VSVg
concentration for each virus to obtain its specific entry activity. Error bars indicate the SEM. A) Virion stiffness or B) specific viral entry activity is
plotted against GFP-TM1 incorporation levels normalized to corresponding immature/mature virus with 100% GFP-TM1 plasmid input. Immature
(orange open diamonds) and mature (blue open circles) HIV-1 bearing VSVg and GFP-TM1 are shown. Specific entry activity is normalized to the
corresponding immature or mature virus with no GFP-TM1. At least 16 particles were measured for each stiffness value.
Figure 8 GFP-TM1 does not interact with coexpressed viral Env.
Immature HIV-1 bearing both GFP-TM1 and JRFL ΔCT Env was
treated with or without 0.5% TX100. Anti-CT, anti-gp120 and anti-CA
antibodies were used to detect GFP-TM1, ΔCT Env (unprocessed
gp140 or processed gp120), and Gag (MA/p6 - full length, MA/CA –
full length missing p6), respectively.
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reduction is due to overexpression of an exogenous
protein (e.g., GFP-TM1) on the viral membrane. To test
this hypothesis, we employed another membrane protein,
PLAP (human placental alkaline phosphatase), to see
whether exogenous protein overexpression causes a simi-
lar modest reduction of viral entry. PLAP is a cell surface,
glycosylphosphatidylinositol anchored protein, and is not
normally present on the lymphoid cell surface [22]. As
with GFP-TM1, we cotransfected ΔCT Env (HXB2 strain)
with titrating PLAP plasmid levels to produce immature
and mature HIV-1 virions. Increasing PLAP incorpor-
ation induces modest reduction of viral entry activity in
both mature and immature virions, similar to the effect
of GFP-TM1 incorporation on mature viral entry
(Figure 9).
Discussion
In this study, we investigated whether HIV-1 employs vari-
ation in particle stiffness as a novel regulatory mechanism
for viral entry. Since both stiffness and viral entry are regu-
lated by a single protein (HIV-1 Env), we separated the
stiffness-regulating CT domain and entry-mediating Env
ectodomain to independently modulate these two proper-
ties. A membrane-anchored CT construct, GFP-TM1, is
sufficient to regulate immature particle stiffness in a similar
Figure 9 PLAP incorporation causes mild reduction of viral
entry activity in both mature and immature viruses. Different
amounts of PLAP were incorporated in the immature (diamond) or
mature (circle) HIV-1 particles bearing ΔCT Env. PLAP incorporation
level was calculated as a PLAP:Gag ratio normalized to virus with
100% PLAP plasmid input. Specific entry activity indicates viral entry
activity per Env, normalized to that of virus with no PLAP input. Error
bars indicate the SEM.
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with coexpressed entry-mediating Env (ΔCT Env or VSVg).
Since GFP-TM1 incorporation showed an immature-
specific effect on viral entry activity, we conclude that in-
creasing particle stiffness is the most likely mechanism by
which GFP-TM1 incorporation progressively inhibits im-
mature viral entry. An important caveat for these results is
that measured Env levels may also include microvesicle-
associated Env, which may not be removed by our virion
pelleting procedure. However, the linear relationship be-
tween viral entry activity and measured Env incorporation
(Figure 10B) suggests a close correlation to virion-
associated Env.
HIV-1 gp41 undergoes significant conformational
changes to bring the viral and cellular membranes into
close proximity to achieve membrane fusion. A likely
mechanism by which particle stiffness affects viral entry ac-
tivity is that stiffer particles may present a higher energy
barrier to membrane deformation during fusion. Deter-
mining which step of entry is regulated by particle stiffness
may help to further characterize this regulatory mechan-
ism. We also showed that particle stiffness regulates viral
entry mediated by the unrelated VSVg. Therefore, targeting
particle stiffness (e.g., by preventing the stiffness switch
during viral maturation), may represent a novel and gen-
eral viral inhibitory strategy.Gag is the major HIV structural protein, and the stiffness
switch during HIV-1 maturation likely originates from
changes in the Gag shell organization, which are visible by
EM as a dramatic decrease in the thickness of the
membrane-associated protein layer (thought to only con-
sist of MA). MA relies on its N-terminal myristoyl group
for membrane binding, and separation of Gag components
from MA was shown to partially bury its myristoyl group,
which destabilizes membrane binding and MA’s oligomeric
structure [23,24].
Current estimates of the number of HIV-1 Env spikes
present on the viral surface are very low (~10 trimers per
virion), compared to up to 2,000 Gag molecules in the
immature virion protein shell [25-28]. An interesting ques-
tion is how so few CT domains can dramatically alter a
global property like particle stiffness in ~100 nm particles.
We propose two possibilities: 1) CT functions during
assembly to seed a specific packing arrangement of the
Gag lattice (analogous to seeding of different crystal
forms), 2) CT functions via its interaction with Gag to
stabilize the whole Gag shell. Future studies may distin-
guish between these two models by establishing the timing
of CT’s regulation of particle stiffness (e.g., during budding
vs. in released immature particles).
Interestingly, the fusion activity of mature HIV-1 is
also blocked by a cholesterol-binding compound,
AME [29]. Virions with CT truncations are AME-
resistant [30]. HIV-1 virions are enriched in choles-
terol as a consequence of their budding from lipid
rafts [31,32], which raises the question whether lipid
membrane components, especially cholesterol, are also
important for particle stiffness. It is therefore tempt-
ing to speculate that AME may inhibit viral entry by
stiffening mature particles, and AME resistance
emerges by severing of the link between Env CT and
Gag (via CT truncation).
Ultimately, mapping of the CT determinants
involved in mediating stiffness and structural studies
of the Gag/CT interaction will be required to reveal
how CT affects the overall Gag shell organization. Fu-
ture studies will also examine why HIV regulates entry
activity via particle stiffness. Possibilities include pre-
vention of viral entry until particle maturation is
complete (to avoid non-productive entry, as suggested
by [15]) or use of the immature virion as a more dur-
able particle to facilitate distant spread of infection.Conclusions
Overall, these results demonstrate the first direct link-
age between a viral physical property and its biological
activity. Future mechanistic and functional studies of
viral particle stiffness may enable the design of novel
entry inhibitors that exploit this linkage.
Figure 10 Optimization of BlaM viral entry assay. A). Immature ΔCT HIV-1 viruses. BlaM signal is plotted against relative amount of loaded
virus. B). Immature HIV-1 bearing titrating amounts of ΔCT Env. Entry signal per virion is plotted against gp120 per virion (determined by WB),
both normalized to virus with 100% ΔCT plasmid input. BlaM assay signal increases proportionally to gp120 concentration (linear fit). C).
Immature HIV-1 bearing titrating amounts of VSVg. Entry signal per virion is plotted against VSVg per virion, both normalized to virus with 100%
VSVg plasmid input. BlaM assay signal increases proportionally to VSVg concentration (linear fit). D). Immature HIV-1 bearing different levels of
BlaM. Entry signal per virion is plotted against BlaM per virion, both normalized to virus with 100% BlaM plasmid input. 2–fold variation of BlaM
concentration minimally changes the entry assay signal. Error bars indicate the standard error of the mean (SEM).
Table 1 Plasmids used in this study
ΔEnv HIV-1 genome vector DHIV3-GFP-D116G





β-lactamase expression vector pMM310
GFP-TM1 expression vector pEBB-HXB2 GFP-TM1
PLAP expression vector pCMV-SPORT6 PLAP
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Plasmids
Plasmids were obtained or constructed as follows (sum-
marized in Table 1): ΔEnv HIV-1 genome vector contain-
ing an inactivating integrase mutant (DHIV3-GFP-D116G
[33], provided by V. Planelles), HIV-1 Env expression
vector (pEBB-HXB2 [34], provided by B. Chen), VSVg
expression vector (phCMV-VSV-G [35,36], provided by
W. Sundquist), Env expression plasmid for JRFL strain
(pCAGGS-JRFL-Env WT and ΔCT, provided by J. Binley
[37]) and vector expressing Vpr-ß-lactamase (BlaM-Vpr)
fusion protein, pMM310 [14]. Human placental alkaline
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was from ATCC. Immature particles were generated by
cloning Gag with all PR cleavage sites mutated (pNL-MA/
p6 [14], provided by C. Aiken) into the ΔEnv Int −HIV-1
genome, while mature particles were produced using an
HIV-1 genome vector with wild-type (WT) cleavage sites.
ΔCT HXB2 Env (Δ147 [38]) was provided by E. Hunter
and cloned into pEBB-HXB2.
To construct GFP-TM1, the GFP (green fluorescent
protein) gene was obtained from pET9a-GFP-C37 [39] by
PCR using a 5′ KpnI-containing primer (5′-tctgggtacc
tagctctggcatggtgagcaagggcgagg) and a 3′ SacI-containing
primer (5′-ctcgaggagctcttgtacag). The gp41 TM+CT frag-
ment was obtained from pEBB-HXB2 by PCR using 5′
SacI-containing primer (5′-caatgagctctggcggttggaattgg
tttaacataacaaattgg) and 3′ BamHI-containing primer
(5’-gtcccagataagtgctaaggatc). These two PCR products
were annealed at the SacI digestion site. The generated
GFP-TM1 fusion fragment was ligated into pEBB-HXB2
to replace the corresponding KpnI-BamHI fragment,
which includes Env residues from V44 to L681 (HXB2
numbering).
Viral preparation and analysis
Pseudovirion particles were produced by cotransfection
of 293T cells with ΔEnv Int- HIV-1 genome vector, an
Env-expressing vector (WT or ΔCT), pMM310, and
pEBB-GFP-TM1. To generate control immature or ma-
ture WT virus, 2.5 μg of total DNA (1.23 μg genome
vector, 0.819 μg Env expressing vector, and 0.45 μg
pMM310) was transfected into ~106 cells using 10 μg
polyethylenimine (PEI, Sigma). In most experiments, the
amount of only one functional plasmid (Env-expressing
vector, pMM310 or pEBB-GFP-TM1) is titrated, and an
inactive balancer plasmid is added to keep total plasmid
concentration constant in a titration series. The amount
of each plasmid used in the control transfection
(described above) is defined as 100%. 100% GFP-TM1,
VSVg or PLAP input is the same as that of WT or ΔCT
Env (0.819 μg). Unless otherwise indicated, the same
amount of genome vector (1.23 μg) and pMM310 vector
(0.45 μg) was used for all transfections. For Env/GFP-
TM1 cotransfections, the Env input was kept constant at
100%, while GFP-TM1 levels were titrated. Media was
changed 6 h after transfection to avoid PEI toxicity.
Supernatants containing secreted viral particles were
collected 30 h post-transfection and filtered through
0.2 μm Acrodisc syringe filters (Pall). Each series of
viruses prepared on the same day is defined as one
“batch”.
For western blot (WB) analysis of viral concentration
and Env incorporation level, virus supernatants were
purified by centrifugation through a sucrose cushion
(20% sucrose in TNE buffer: 0.1 M NaCl, 1 mM EDTA,10 mM Tris, pH 7.6) at 20,000 X g for 90 min at 4°C. A
caveat of this method is that pelleted samples may also
include vesicle-associated Env, which is difficult to dis-
tinguish from virion-associated Env. Since intact virions
are needed to incorporate BlaM-Vpr, this caveat does
not influence entry activity measurements, but may
affect the accuracy of measured Env incorporation levels.
The pellet was resuspended in SDS-PAGE reducing sam-
ple buffer and resolved by SDS-PAGE. WB was devel-
oped using rabbit polyclonal anti-CA and anti-VSVg
(provided by W. Sundquist), mouse monoclonal anti-
gp41 CT antibody (obtained from Chessie 8 hybridoma
contributed by G. Lewis, NIH AIDS Research and Refer-
ence Reagent Program (ARRRP)), and sheep polyclonal
anti-gp120 (contributed by M. Phelan, ARRRP). Second-
ary antibodies are goat anti-rabbit (IRDye 680, Li-Cor),
donkey anti-mouse (IRDye 800, Li-Cor) and Rabbit anti-
sheep (IRDye 800, Rockland). Blots were quantified
using a Li-Cor Odyssey infrared scanner. GFP-TM1 and
WT Env incorporation levels per virion were calculated
as a CT:Gag ratio. ΔCT Env and VSVg incorporation
levels were calculated as gp120:Gag and VSVg:Gag
ratios, respectively. PLAP was detected by rabbit mono-
clonal anti-PLAP antibody (Abcam, ab16695).
AFM measurement and analysis
For AFM measurements, virus-containing supernatant was
first concentrated as previously described [40]. Briefly, the
filtered viral supernatant was pelleted onto a 5 ml cushion
of OPTI-PREP (Iodixanol, Sigma) in a SW-28 rotor
(21,000 rpm, 90 min, 4°C). ~90% of the upper layer super-
natant was then aspirated, and the lower layer supernatant
was collected with a syringe, combined with 3–5 volumes
of TNE buffer, and concentrated by centrifugal ultrafiltra-
tion with a MWCO of 100,000 (Vivaspin 20, Sartorius)
three times at 3,000 X g.
For AFM imaging and force measurements, virus par-
ticles were attached to HMDS-coated microscope glass
slides using previously described methods [13,40]. All
AFM experiments were carried out using a Bioscope
with a Nanoscope IV controller (Veeco) equipped with a
dimension XY closed loop scanner mounted on an
inverted optical microscope (Axiovert 200 M, Carl Zeiss
AG). Images of virus particles were acquired in AFM
tapping mode in a fluid environment (TNE buffer). Py-
ramidal silicone nitride probes either mlct (K = 1 N/m,
Veeco) or NSC35 (K = 3-7 N/m, Micromasch) were
used. The spring constants of the DNP probes were
determined experimentally by measuring thermal fluc-
tuations [41]. Since the amplitude of the NSC35 thermal
fluctuations was too low, we used the method of Sader
et al. [20] to determine their spring constants.
Virus stiffness was determined based on indentation
type experiments, as previously described [9,13]. Briefly,
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(FD) curves were performed at a scan rate of 0.5 Hz.
Viral stiffness was derived mathematically from the slope
of the FD curve. The stiffness of the virus was computed
according to Hooke’s law on the assumption that our ex-
perimental system can be modeled as two springs (the
virus and the cantilever) arranged in series. In this study,
virus particles had a relatively wide range of point stiff-
nesses, which required using several types of cantilevers
having different spring constants. In order to reduce
error in the virus calculated point stiffness, we prefer
that the measured point stiffness is not larger than 70%
of the cantilever spring constant. If the majority of virus
measured point stiffness values are larger than this
threshold we use a stiffer cantilever to measure these
particles. Particles are selected for measurement based
on their appearance in AFM imaging in tapping mode
(roughly round particles with 80–120 nm height and lit-
tle background debris near them). Particles are excluded
if particle stiffness rises or drops dramatically during
measurement (reflecting poor virion attachment to the
surface or irreversible “breaking”, respectively).
ß-lactamase (BlaM) assay for viral entry measurement
The viral entry assay was performed as described [13].
Briefly, viruses mixed with DEAE-Dextran (4 μg/ml)
were added onto HOS-CD4-CXCR4 cells (provided by
B.Chen), followed by centrifugation at 1800 X g for
30 min at 4°C and then incubated at 37°C for 2 h. After
aspiration of unbound viruses, 1 μM ß-lactamase sub-
strate solution (CCF2-AM, Invitrogen) was incubated
with cells at 13°C for 17 h. Uncleaved and cleaved
CCF2-AM have emission peaks of 520 nm (green) and
447 nm (blue), respectively, under 409 nm excitation.
Fluorescent signals from both channels were detected
using an Olympus MVX10 fluorescent microscope and
quantified using ImageJ software. The ratio of blue vs.
green fluorescent signal was calculated as the BlaM assay
signal. Each assay was performed in triplicate and their
BlaM assay signals were averaged as the entry signal. In
this assay, entry signal increases proportionally to the
amount of virus added (Figure 10A). gp120 represents
functional HIV-1 Env that is cleaved by cellular pro-
teases and capable of mediating viral entry. To investi-
gate the relationship between gp120 concentration and
BlaM assay signal, immature viruses bearing different
amounts of HIV-1 ΔCT Env were generated and mea-
sured for their entry activities. Entry signal per viral par-
ticle also increases proportionally with the amount of
processed Env (gp120) per viral particle, showing that
the BlaM assay signal depends on the processed Env
concentration (Figure 10B).
Therefore, viral entry activity was normalized to gp120
levels for each GFP-TM1 titration series. The specificentry activity we report here represents the viral entry
activity per processed Env. Relative viral entry activity
was calculated by normalization of the entry activity of
each virus to that of virus without GFP-TM1. For all
measurements, the mean entry activities from at least
two independent batches assayed separately are
reported.
The BlaM assay signal also increases proportionally to
VSVg incorporation level (Figure 10C), so VSV-specific
entry activity was also normalized to VSVg levels. Simi-
larly, a varying amount of pMM310 was used during
transfection to create a series of viruses bearing titrating
amounts of BlaM (detected by rabbit polyclonal anti-
BlaM (Chemicon/Millpore)). 2-fold variation of BlaM
incorporation level only slightly changed the BlaM assay
signal (Figure 10D). Since anti-BlaM Western blots
showed less than 2-fold variation in BlaM incorporation
levels for all our GFP-TM1 titrating viruses (data not
shown), BlaM incorporation level was not considered
during normalization.
To investigate whether we can compare the entry ac-
tivity of viruses from different batches, normalized entry
activities of immature VSVg pseudovirions without GFP-
TM1 were measured and found to be very similar be-
tween different batches (data not shown). Therefore, the
entry activity of viruses is reported as a relative value to
that of virus with no GFP-TM1 within each series.
Triton X-100 (TX100) treatment
TX100 treatment of HIV-1 particles was performed as
described previously [6]. Briefly, virus-containing super-
natant was first concentrated using the sucrose cushion
method described above. The pellet was then resuspended
into 0.5% TX100 in TNE buffer and incubated at 4°C for
30 min before centrifugation in a Beckman TLA-55 rotor
at 45,000 rpm for 30 min. After centrifugation, the pellet
was resuspended in SDS-PAGE reducing sample buffer
and analyzed by Western blot. WB was developed using
primary antibodies (rabbit anti-CA, mouse anti-gp41 CT
and sheep anti-gp120) and secondary antibodies (goat anti-
rabbit, donkey anti-mouse and rabbit anti-sheep) described
above and quantified using a Li-Cor Odyssey infrared
scanner.
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